IRF-2BP1 Activators
IRF-2BP1 Activators are a class of chemical compounds that can enhance the functional activity of IRF-2BP1, a transcriptional co-regulator that plays a crucial role in cellular processes such as apoptosis and cell cycle regulation. These compounds exert their effect either directly or indirectly, by primarily influencing the cellular signaling pathways that IRF-2BP1 is involved in. For instance, JQ1, I-BET762 and I-BET151 are known to inhibit BRD4, a protein that interacts with IRF-2BP1. By inhibiting BRD4, these compounds disrupt its interaction with IRF-2BP1, thus preventing the repression of IRF-2BP1 and leading to its activation.
The other compounds in this class, such as tranylcypromine, and nutlin-3a, operate through similar mechanisms, influencing the IRF2 signaling pathway where IRF-2BP1 is involved. Tranylcypromine, being a monoamine oxidase inhibitor, could increase the concentration of certain neurotransmitters, indirectly enhancing the activity of IRF-2BP1. Nutlin-3a inhibits MDM2, a protein that interacts with IRF-2BP1, and this inhibition allows for the increased activity of IRF-2BP1 by preventing MDM2 from repressing it. In the same vein, other compounds like Z-DEVD-FMK, MG132, SP600125, PD98059, VX-765, and SB203580, exert their influence by inhibiting specific enzymes or proteins, thereby indirectly enhancing the activity of IRF-2BP1 through the IRF2 signaling pathway.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is a BET bromodomain inhibitor that targets BRD4, a protein known to interact with IRF-2BP1. This interaction inhibits the transcriptional repression activity of IRF-2BP1, thus leading to its activation. | ||||||
GSK 525762A | 1260907-17-2 | sc-490339 sc-490339A sc-490339B sc-490339C sc-490339D | 5 mg 10 mg 50 mg 100 mg 1 g | $300.00 $540.00 $940.00 $1680.00 $5900.00 | ||
I-BET762 is another BET bromodomain inhibitor, which targets BRD4. By inhibiting BRD4, it disrupts its interaction with IRF-2BP1, thereby preventing the repression of IRF-2BP1 and leading to its activation. | ||||||
I-BET 151 Hydrochloride | 1300031-49-5 (non HCl Salt) | sc-391115 | 10 mg | $450.00 | 2 | |
I-BET151 is a BET bromodomain inhibitor that targets both BRD3 and BRD4, proteins known to interact with IRF-2BP1. By inhibiting these proteins, I-BET151 prevents their interaction with IRF-2BP1, leading to the activation of IRF-2BP1. | ||||||
Tranylcypromine | 13492-01-8 | sc-200572 sc-200572A | 1 g 5 g | $175.00 $599.00 | 5 | |
Tranylcypromine is a monoamine oxidase inhibitor that could increase the concentration of certain neurotransmitters, potentially influencing the IRF2 signaling pathway, and thus indirectly enhancing the activity of IRF-2BP1. | ||||||
(–)-Nutlin-3 | 675576-98-4 | sc-222086 sc-222086A | 1 mg 5 mg | $122.00 $219.00 | 2 | |
Nutlin-3a inhibits MDM2, a protein that interacts with IRF-2BP1. This inhibition allows for the increased activity of IRF-2BP1 by preventing MDM2 from repressing it. | ||||||
Caspase-3 Inhibitor | 210344-95-9 | sc-3075 | 0.5 mg | $112.00 | 57 | |
Z-DEVD-FMK is a caspase-3 inhibitor. This inhibition may indirectly enhance the activity of IRF-2BP1 through the IRF2 signaling pathway by preventing the initiation of apoptosis. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of proteins involved in the IRF2 signaling pathway, indirectly leading to the activation of IRF-2BP1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. This inhibition may indirectly enhance the activity of IRF-2BP1 through the IRF2 signaling pathway by preventing JNK-mediated signaling events. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor. This inhibition may indirectly enhance the activity of IRF-2BP1 through the IRF2 signaling pathway by preventing MEK-mediated signaling events. | ||||||
VX-765 | 273404-37-8 | sc-475845 sc-475845A sc-475845B | 5 mg 10 mg 50 mg | $228.00 $302.00 $968.00 | 1 | |
VX-765 is a caspase-1 inhibitor. This inhibition may indirectly enhance the activity of IRF-2BP1 through the IRF2 signaling pathway by preventing the initiation of inflammation. | ||||||